Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

April 17, 2018

NEWARK, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced the appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications, effective immediately.

Mr. Thomas most recently served as Executive Vice President, Corporate Strategy and Investor Relations at Horizon Pharma. Prior to that, he served nearly 20 years at Abbott Laboratories, most recently, as Vice President, Investor Relations and Public Affairs and President of the Abbott Fund.

“John is one of the most experienced and trusted Investor Relations Officers in the global healthcare industry,” said Arthur Higgins, President and CEO of Depomed. “He brings valuable relationships on Wall Street as well as a keen understanding of Capital Markets and IR best practices. I’m confident John will make significant contributions to our strategic direction, long-term growth and shareholder valve creation.”

Mr. Thomas received his M.B.A. from The Lake Forest Graduate School of Management and a B.A. in journalism from The University of Mississippi.

About Depomed

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its neurology and pain franchises and its emerging specialty/orphan franchise is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to risks detailed in the Company's Securities and Exchange Commission filings, including the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Investor and Media Contact:

John Thomas
SVP Investor Relations and Corporate Communications
jthomas@depomed.com

Dan Peisert
VP, Business Development
dpeisert@depomed.com

Primary Logo

Source: Depomed, Inc.